BD (Becton, Dickinson and Company), a global medical technology company, and Quest Diagnostics, a leader in diagnostic information services, have agreed to develop, manufacture, and commercialize flow cytometry-based companion diagnostics. The solutions are intended to help select the best treatment for patients with cancer and other diseases. Current companion diagnostic tests commonly involve technologies such as immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction, next-generation sequencing, and imaging. “This strategic collaboration with BD will combine our expertise in developing and validating biomarkers and assays with BD's leadership in flow cytometry to offer a fully integrated solution on a larger scale," said William Finger, vice president and general manager, Pharma Services for Quest Diagnostics. In 2022, BD entered into a collaboration with Labcorp, also targeting flow-cytometry-based diagnostics. Labcorp and Quest are market leaders in laboratory diagnostics. BD and Quest will aim to provide the pharmaceutical industry with an end-to-end solution for companion diagnostics development. The joint offerings will range from exploratory panel development to the manufacturing and distribution of FDA-approved diagnostic kits.